Bliss GVS Pharma Limited , a prominent player in the Indian pharmaceutical sector, has taken a significant step to incentivize its workforce. The company's Nomination and Remuneration Committee approved the grant of 5,53,000 stock options to eligible employees under its Employee Stock Options Plan 2019.

Key Details of the Stock Option Grant

Vesting and Exercise Details

The stock options will vest in four equal installments over four years, with each tranche representing 25% of the total granted options. This staggered vesting schedule aims to promote long-term employee retention and align employee interests with those of the company's shareholders.

Once vested, employees will have a window of six months to exercise their options.

Potential Impact on Employee Retention and Motivation

By offering these stock options at a substantial discount of 72.05% to the market price, Bliss GVS Pharma is providing a potentially lucrative opportunity for its employees. This move may serve to:

1. Enhance employee loyalty and retention
2. Align employee interests with company performance
3. Attract top talent in a competitive pharmaceutical industry

Additional Corporate Updates

Bliss GVS Pharma also announced significant changes in its leadership:

1. Resignation of Managing Director: Mr. Gagan Harsh Sharma has resigned from his position as Managing Director, effective immediately, citing other professional commitments.

2. New Senior Management Appointment: Mr. Shreekrushna Joshi has been appointed as Head – Legal and designated as Senior Management Personnel, bringing over 15 years of experience in corporate legal and secretarial compliance.

These changes in the company's leadership structure, coupled with the employee stock option grant, signal a period of transition for Bliss GVS Pharma.

Bliss GVS Pharma Limited , a prominent player in the pharmaceutical sector, has recently expanded its share capital through the allotment of equity shares under its Employee Stock Option Plan (ESOP). This move underscores the company's commitment to employee incentivization and aligns with its growth strategy.

Key Details of the Allotment

The ESOP Allotment Committee of Bliss GVS Pharma approved the issuance of 33,670 equity shares on November 5, 2025. These shares, each with a face value of Re. 1, were allotted to eligible employees who exercised their stock options under the company's Employee Stock Option Plan 2019 (Bliss GVS ESOP-2019).

Impact on Share Capital

Following this allotment, the company's share capital structure has undergone the following changes:

Financial and Regulatory Aspects

• Exercise Price: The shares were allotted at an exercise price of Rs. 43.00 per share, which includes a premium of Rs. 42.00 per share.
• Lock-in Period: The newly allotted shares are subject to a lock-in period of six months from the date of allotment, set to expire on May 5, 2026.
• Listing: The shares are expected to be listed on both the BSE Limited and the National Stock Exchange of India Limited, where the company's existing shares are traded.
• ISIN: The allotted shares carry the ISIN INE416D01022, consistent with the company's existing equity shares.

Regulatory Compliance

This allotment is in compliance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has duly informed the stock exchanges about this corporate action, adhering to the principles of transparency and regulatory disclosure.

Implications for Investors and Employees

For existing shareholders, this allotment represents a marginal dilution of 0.03% in their shareholding. However, it also signifies the company's focus on aligning employee interests with those of the shareholders, potentially driving long-term value creation.

For the employees who received these shares, it presents an opportunity to participate in the company's equity and benefit from its future growth, subject to the specified lock-in period.

As Bliss GVS Pharma continues to navigate the dynamic pharmaceutical landscape, this ESOP allotment serves as a testament to its strategy of fostering employee engagement and retention through equity participation.